Table summarizing the response, OS, relapse, and clonal evolution in refractory AA patients treated with alemtuzumab-based IST
| Reference . | Study design . | Indication . | N . | Alemtuzumab regimen . | CSA . | Response . | OS . | Relapse . | Clonal evolution . |
|---|---|---|---|---|---|---|---|---|---|
| Scheinberg et al18 | Prospective randomized | Refractory to hATG + CSA | 27 | 10 mg/kg/d × 10 IV | None | 37% | 83% at 3 y | 3 | 1 (−7) |
| Risitano et al19 | Prospective phase 2 | Untreated (n = 6); refractory (n = 5) | 11 | 3, 10, 30, 30 and 30 mg/d SC (total dose 103 mg) | 1 mg/kg/d | 8/11 (73%) (4/6 untreated) | 73% | 2 | - |
| 3 | - | ||||||||
| Retrospective | Refractory | 8 | 3/8 (37%) | ||||||
| Kim et al20 | Prospective dose escalating | Untreated (n = 13) Refractory to ATG + CSA/danazol (n = 4) | 17 | Cohort I: 10, 20, 30 mg IV Cohort II: 30 mg/d × 3 IV | 3 mg/kg/d | 4/13 (31%) 2/4 (50%) | 81.6% at 2 y | 1 | 1 (MDS) |
| Reference . | Study design . | Indication . | N . | Alemtuzumab regimen . | CSA . | Response . | OS . | Relapse . | Clonal evolution . |
|---|---|---|---|---|---|---|---|---|---|
| Scheinberg et al18 | Prospective randomized | Refractory to hATG + CSA | 27 | 10 mg/kg/d × 10 IV | None | 37% | 83% at 3 y | 3 | 1 (−7) |
| Risitano et al19 | Prospective phase 2 | Untreated (n = 6); refractory (n = 5) | 11 | 3, 10, 30, 30 and 30 mg/d SC (total dose 103 mg) | 1 mg/kg/d | 8/11 (73%) (4/6 untreated) | 73% | 2 | - |
| 3 | - | ||||||||
| Retrospective | Refractory | 8 | 3/8 (37%) | ||||||
| Kim et al20 | Prospective dose escalating | Untreated (n = 13) Refractory to ATG + CSA/danazol (n = 4) | 17 | Cohort I: 10, 20, 30 mg IV Cohort II: 30 mg/d × 3 IV | 3 mg/kg/d | 4/13 (31%) 2/4 (50%) | 81.6% at 2 y | 1 | 1 (MDS) |
hATG indicates horse ATG.